These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28406934)

  • 21. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
    Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computed-tomography-guided anatomic standardization for quantitative assessment of dopamine transporter SPECT.
    Yokoyama K; Imabayashi E; Sumida K; Sone D; Kimura Y; Sato N; Mukai Y; Murata M; Matsuda H
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):366-372. PubMed ID: 27544223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease.
    Thaler A; Shenhar-Tsarfaty S; Shaked Y; Gurevich T; Omer N; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Giladi N; Mirelman A
    Sci Rep; 2020 Jun; 10(1):9329. PubMed ID: 32518334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel.
    Hassin-Baer S; Laitman Y; Azizi E; Molchadski I; Galore-Haskel G; Barak F; Cohen OS; Friedman E
    J Neurol; 2009 Mar; 256(3):483-7. PubMed ID: 19412725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
    Agalliu I; San Luciano M; Mirelman A; Giladi N; Waro B; Aasly J; Inzelberg R; Hassin-Baer S; Friedman E; Ruiz-Martinez J; Marti-Masso JF; Orr-Urtreger A; Bressman S; Saunders-Pullman R
    JAMA Neurol; 2015 Jan; 72(1):58-65. PubMed ID: 25401981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.
    Rahmim A; Salimpour Y; Jain S; Blinder SA; Klyuzhin IS; Smith GS; Mari Z; Sossi V
    Neuroimage Clin; 2016; 12():e1-e9. PubMed ID: 27995072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olfactory dysfunction in LRRK2 G2019S mutation carriers.
    Saunders-Pullman R; Stanley K; Wang C; San Luciano M; Shanker V; Hunt A; Severt L; Raymond D; Ozelius LJ; Lipton RB; Bressman SB
    Neurology; 2011 Jul; 77(4):319-24. PubMed ID: 21753159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
    Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Glinka T; Goldstein O; Kestenbaum M; Cedarbaum JM; Mabrouk OS; Fraser KB; Shirvan JC; Orr-Urtreger A; Mirelman A; Thaler A
    Mov Disord; 2022 Jan; 37(1):190-195. PubMed ID: 34550621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers.
    van den Heuvel L; Lim AS; Visanji NP; Huang J; Ghate T; Mestre TA; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Pondal M; Faust-Socher A; Rogaeva E; Tomlinson G; Lang AE; Marras C
    J Parkinsons Dis; 2018; 8(1):131-139. PubMed ID: 29480219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease.
    Bergareche A; Rodríguez-Oroz MC; Estanga A; Gorostidi A; López de Munain A; Castillo-Triviño T; Ruiz-Martínez J; Mondragón E; Gaig C; Lomeña F; Sarasqueta C; Tolosa E; Martí-Massó JF
    Mov Disord; 2016 Mar; 31(3):335-43. PubMed ID: 26686514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The heterozygous R1441C mutation of leucine-rich repeat kinase 2 gene in a Chinese patient with Parkinson disease: A five-year follow-up and literatures review.
    Peng F; Sun YM; Chen C; Luo SS; Li DK; Wang YX; Yang K; Liu FT; Zuo CT; Ding ZT; An Y; Wu JJ; Wang J
    J Neurol Sci; 2017 Feb; 373():23-26. PubMed ID: 28131193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
    Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
    Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the LRRK2 gene.
    Mirelman A; Alcalay RN; Saunders-Pullman R; Yasinovsky K; Thaler A; Gurevich T; Mejia-Santana H; Raymond D; Gana-Weisz M; Bar-Shira A; Ozelius L; Clark L; Orr-Urtreger A; Bressman S; Marder K; Giladi N;
    Mov Disord; 2015 Jun; 30(7):981-6. PubMed ID: 25809001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
    Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
    Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease.
    Sánchez-Rodríguez A; Tirnauca C; Salas-Gómez D; Fernández-Gorgojo M; Martínez-Rodríguez I; Sierra M; González-Aramburu I; Stan D; Gutierrez-González A; Meissner JM; Andrés-Pacheco J; Rivera-Sánchez M; Sánchez-Peláez MV; Sánchez-Juan P; Infante J
    Parkinsonism Relat Disord; 2022 May; 98():21-26. PubMed ID: 35421781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuromelanin and T
    Ben Bashat D; Thaler A; Lerman Shacham H; Even-Sapir E; Hutchison M; Evans KC; Orr-Urterger A; Cedarbaum JM; Droby A; Giladi N; Mirelman A; Artzi M
    NPJ Parkinsons Dis; 2022 Oct; 8(1):139. PubMed ID: 36271084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved prediction of outcome in Parkinson's disease using radiomics analysis of longitudinal DAT SPECT images.
    Rahmim A; Huang P; Shenkov N; Fotouhi S; Davoodi-Bojd E; Lu L; Mari Z; Soltanian-Zadeh H; Sossi V
    Neuroimage Clin; 2017; 16():539-544. PubMed ID: 29868437
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A;
    Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.